Key result
Intravenous recombinant tissue plasminogen activator reduced 14-day mortality by 51% (95% CI -76 to 1) and decreased enzymatic infarct size by 20% (P=0.0018) in acute myocardial infarction.
Why the study?
Does intravenous recombinant tissue type plasminogen activator improve survival, reduce infarct size, and preserve left ventricular function in patients with acute myocardial infarction within five hours of symptom onset?
RCT (n=721)
Double blind
randomised
Yes
Does intravenous recombinant tissue type plasminogen activator improve survival, reduce infarct size, and preserve left ventricular function in patients with acute myocardial infarction within five hours of symptom onset?
Answers are grounded in this paper and cite their sources.
Intravenous recombinant tissue plasminogen activator administered within 5 hours of acute myocardial infarction reduces infarct size, preserves LV function, and reduces mortality, albeit with an increased risk of bleeding.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Werf et al. (1988) conducted an RCT in acute myocardial infarction (n=721). Intravenous recombinant tissue type plasminogen activator vs. Placebo was evaluated on Left ventricular function at 10-22 days, enzymatic infarct size, clinical course, and survival to three month follow up (51% reduction in mortality at 14 days, 95% CI -76 to 1). Intravenous recombinant tissue plasminogen activator reduced 14-day mortality by 51% (95% CI -76 to 1) and decreased enzymatic infarct size by 20% (P=0.0018) in acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: